This phase in the path to clinical use of DPP-4 inhibitors was followed with a rapid development during the 2000s with clinical studies of several different DPP-4 inhibitors which ended in 2006–2013 with their approval for use in subjects with type 2 diabetes. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.